Bextra Physician Letter Could Be Additional Boon For OTC NSAIDs
This article was originally published in The Tan Sheet
Executive Summary
Pfizer will conduct further studies on the long-term cardiovascular safety profile ofBextra (valdecoxib), following results from two studies in surgical settings that showed an increase in cardiovascular events in patients taking the COX-2 arthritis treatment